A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers
Description
Brief Summary
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and
expansion study evaluating AFM24 in combination with atezolizumab in patients with selected
EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with
previous anticancer therapies.
Detailed Description
There will be 2 parts in this study: a dose escalation phase (phase 1) and an expansion phase
(phase 2a). Patients will qualify to receive the investigational drugs (AFM24 + atezolizumab)
in the dose escalation phase or the expansion phase only if they are deemed eligible
following the safety lead-in phase. Seven days before the planned first combination
treatment, patients will receive a single dose of AFM24 and will be observed for any adverse
events for 1 week.
The aim of the dose escalation phase is to determine the maximum tolerated dose
(MTD)/recommended phase 2 dose (RP2D) of AFM24 in combination with atezolizumab.
The dose escalation phase will be followed by the expansion phase once the MTD/RP2D of AFM24
in combination with atezolizumab has been determined. The expansion phase of the study is
intended to collect preliminary evidence of efficacy and to further confirm the safety of
AFM24 in combination with atezolizumab.
The tumor types planned to be studied in the AFM24/atezolizumab combination study will be:
- Non-small cell lung cancer (EGFR-WT), with disease progression after chemotherapy and
PD1/PD-L1 targeted therapy
- Gastric/GEJ cancer if intolerant to or with disease progression after standard
platinum-based chemotherapy
- Pancreatic/hepatocellular/biliary tract cancer with disease progression after standard
of care (SOC) therapy or if there is no appropriate SOC available for their condition
Phase
N/AInclusion and Exclusion Criteria
- Histologically or cytologically confirmed advanced or metastatic EGFR-positive selected cancer types:
- Advanced or metastatic NSCLC, EGFR WT: disease has progressed after ≥ 1 prior lines of therapy which must have included a platinum-based doublet in combination with PD1/PD-L1 antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet
- Advanced, unresectable, or metastatic gastric/GEJ adenocarinoma: after ≥ 1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet
- Advanced or metastatic HCC (BCLC C or B not amenable or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma: after ≥1 prior line of an approved SOC therapy for the respective disease type or to whom the available SOC is not appropriate in the opinion of the investigator
- Adequate organ function
- Phase 1: Evaluable or measurable disease per RECIST v1.1
- Phase 2a: Measurable disease per RECIST v1.1
- Treatment with systemic anticancer therapy including investigational agent within 4 weeks of the first dose of study drug, 6 weeks for mitomycin C or nitrosoureas, 2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor indication.
- Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity from previous radiotherapy
- History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer
- Currently active in any other clinical study, or administration of other investigational agent
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Presentado por
SC CTSI